600276 恒瑞医药
已收盘 09-24 15:00:00
资讯
新帖
简况
雅本化学：目前来自恒瑞医药的收入仍未形成规模
格隆汇 · 09-23 23:03
雅本化学：目前来自恒瑞医药的收入仍未形成规模
字节、百度与恒瑞、诺和诺德，抢滩AI制药商业化
蓝鲸财经 · 09-23 20:01
字节、百度与恒瑞、诺和诺德，抢滩AI制药商业化
恒瑞医药(01276)9月23日斥资1137.23万元回购25万股A股
智通财经 · 09-23 17:42
恒瑞医药(01276)9月23日斥资1137.23万元回购25万股A股
恒瑞医药：HRS-7172片等多款药物临床试验获批准
每日经济新闻 · 09-23 16:54
恒瑞医药：HRS-7172片等多款药物临床试验获批准
先声药业周云曙：对外授权是阶段性选择，未来不再简单追求数量
第一财经 · 09-23 10:23
先声药业周云曙：对外授权是阶段性选择，未来不再简单追求数量
“最大教训是创新转型不够快” 先声药业总裁周云曙：希望BD成为公司第二增长曲线
同花顺 · 09-22 14:34
“最大教训是创新转型不够快” 先声药业总裁周云曙：希望BD成为公司第二增长曲线
贝莱德在恒瑞医药的H股好仓比例上升0.06%至7.05%
南方财经网 · 09-21
贝莱德在恒瑞医药的H股好仓比例上升0.06%至7.05%
恒瑞医药：HRS-1596片获临床试验批准
南方财经网 · 09-21
恒瑞医药：HRS-1596片获临床试验批准
恒瑞医药(600276.SH)：注射用SHR-4595获得药物临床试验批准通知书
智通财经 · 09-21
恒瑞医药(600276.SH)：注射用SHR-4595获得药物临床试验批准通知书
花旗：医药工业发展“十五五”规划利好创新药及医疗器械，首选恒瑞医药及信达生物等
同花顺 · 09-21
花旗：医药工业发展“十五五”规划利好创新药及医疗器械，首选恒瑞医药及信达生物等
大行评级丨美银：中国医疗保健行业加快创新及全球化，维持对信达生物、恒瑞医药“买入”评级
格隆汇 · 09-21
大行评级丨美银：中国医疗保健行业加快创新及全球化，维持对信达生物、恒瑞医药“买入”评级
研报掘金丨浙商证券：维持恒瑞医药“买入”评级，非肿瘤新药放量显著，BMS合作再创佳绩
格隆汇 · 09-18
研报掘金丨浙商证券：维持恒瑞医药“买入”评级，非肿瘤新药放量显著，BMS合作再创佳绩
港股异动 | 恒瑞医药(01276)涨近4% 公司首次回购A股 机构看好非肿瘤领域继续贡献产品端增量
智通财经 · 09-18
港股异动 | 恒瑞医药(01276)涨近4% 公司首次回购A股 机构看好非肿瘤领域继续贡献产品端增量
恒瑞医药(600276.SH)首次回购33.5万股 耗资1450.36万元
智通财经 · 09-17
恒瑞医药(600276.SH)首次回购33.5万股 耗资1450.36万元
港股异动 | 恒瑞医药(01276)尾盘涨近4% 同日获两份临床试验批准 覆盖银屑病和卒中预防
智通财经 · 09-16
港股异动 | 恒瑞医药(01276)尾盘涨近4% 同日获两份临床试验批准 覆盖银屑病和卒中预防
创新药概念局部走强 恒瑞医药（01276）涨2.74% 机构料企业扭亏节点到来
金吾财讯 · 09-16
创新药概念局部走强 恒瑞医药（01276）涨2.74% 机构料企业扭亏节点到来
港交所披露：贝莱德增持恒瑞医药H股，持股比例升至7.17%
美股速递 · 09-15
港交所披露：贝莱德增持恒瑞医药H股，持股比例升至7.17%
恒瑞医药：子公司“注射用瑞卡西单抗”获批开展III期临床试验
财中社 · 09-15
恒瑞医药：子公司“注射用瑞卡西单抗”获批开展III期临床试验
恒瑞医药(600276.SH)：HRS-4139片获得药物临床试验批准通知书
智通财经 · 09-15
恒瑞医药(600276.SH)：HRS-4139片获得药物临床试验批准通知书
恒瑞医药：SHR-2004注射液上市许可申请获受理
每日经济新闻 · 09-14
恒瑞医药：SHR-2004注射液上市许可申请获受理
加载更多
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是注射用卡瑞利珠单抗、羟乙磺酸达尔西利片、瑞维鲁胺片、海曲泊帕乙醇胺片、脯氨酸恒格列净片、碘佛醇注射液。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":44.86,"timestamp":1790233200000,"preClose":45.58,"halted":0,"volume":42358438,"delay":0,"changeRate":-0.0158,"floatShares":6379000000,"shares":6637000000,"eps":1.1642,"marketStatus":"已收盘","change":-0.72,"latestTime":"09-24 15:00:00","open":45.38,"high":45.77,"low":44.6,"amount":1902000000,"amplitude":0.0257,"askPrice":44.87,"askSize":31,"bidPrice":44.86,"bidSize":132,"shortable":0,"etf":0,"ttmEps":1.1642,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790559000000},"marketStatusCode":5,"adr":0,"adjPreClose":45.58,"symbolType":"stock","openAndCloseTimeList":[[1790213400000,1790220600000],[1790226000000,1790233200000]],"highLimit":50.14,"lowLimit":41.02,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":4.62,"roa":"--","peRate":38.532898,"roe":"8.04%","epsLYR":1.19,"committee":-0.020946,"marketValue":297745000000,"turnoverRate":0.0066,"status":1,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":45.52,"timestamp":1790237311002,"preClose":47.22,"halted":0,"volume":2878645,"delay":0,"premium":"-13.11"},"floatMarketCap":286162000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2669826904","title":"雅本化学：目前来自恒瑞医药的收入仍未形成规模","url":"https://stock-news.laohu8.com/highlight/detail?id=2669826904","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669826904?lang=zh_cn&edition=full","pubTime":"2026-09-23 23:03","pubTimestamp":1790175814,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","LU2580892862.HKD","LU2580892789.USD","LU1655091616.SGD","LU1781817850.SGD","300261","LU2097828714.EUR","LU0405327494.USD","LU2097828805.USD","BK0174","LU1580142542.USD","BK0012","LU1820825898.SGD","LU1969619763.USD","BK0188","LU1997244956.HKD","BK0060","LU1146622755.USD","LU0405327148.USD","BK0196","LU1997245177.USD","LU1255011170.USD","LU2495084118.USD","BK0183","LU1328615791.USD","LU2488822045.USD","LU1064131003.USD","600276","LU2148510915.USD","LU2289578879.USD","LU2097828557.USD","LU2097828631.EUR","LU2097828474.EUR","LU2328871848.SGD","LU1064130708.USD","BK0229","BK0239","LU1997245094.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669762483","title":"字节、百度与恒瑞、诺和诺德，抢滩AI制药商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2669762483","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669762483?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:01","pubTimestamp":1790164907,"startTime":"0","endTime":"0","summary":"截图来源于港股公告叠加字节跳动将AI制药业务独立拆分设立Anew Labs这一动作，入局AI制药的大厂阵营还在持续扩容。目前，行业已有落地成果佐证AI的前端价值。港股龙头英硅智能的发展路径，展现了当前AI药企的部分商业化现状。截图来源于港股公告这份增速亮眼的财报，证明AI技术具备即时商业变现能力。AI技术模型可以加快新药研发的起点，但从这条赛道跑出来的玩家，大概率是率先实现临床转化与商业化落地的那个。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789979347715387090","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["DRGN","BK4543","LU1093756168.USD","BK4587","BK0183","LU1064131003.USD","BK4614","LU2289578879.USD","BK4585","LU2580892862.HKD","LU1997245094.SGD","BK0239","BK0196","NVOH","BK4579","LU0640798160.USD","LU0287142896.SGD","LU1023057109.AUD","KBDU","OZEM","BK4526","LU0359201612.USD","LU2495084118.USD","NVOC","BK4504","BK0060","BK0012","PPH","IE00BZ1G4Q59.USD","LU2097828805.USD","09888","BK4574","BK0028","IE00B0JY6N72.USD","LU1781817850.SGD","LU1997245177.USD","BK4531","BIDG","LU1093756325.SGD","BK4552","LU1328615791.USD","01276","THNR","LU2097828714.EUR","LU1820825898.SGD","LU1146622755.USD","600276","LU1580142542.USD","02257","BK4602","BK4532","LU0405327148.USD","LU1064130708.USD","LU2580892789.USD","LU1655091616.SGD","LU1115378108.SGD","LU2097828631.EUR","BK4077","BIDU","LU1255011170.USD","NVOX","LU2148510915.USD","BK4535","BK4514","BK4548","BK4599","BK0188","NVO","LU2328871848.SGD","LU2488822045.USD","BK4588","LU0405327494.USD","LU1969619763.USD","LU0173614495.USD","LU1997244956.HKD","BK4612","LU0359202008.SGD","BK4007","BK1161","IE00BKVL7J92.USD","LU2097828474.EUR","LU0154236417.USD","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669104701","title":"恒瑞医药(01276)9月23日斥资1137.23万元回购25万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669104701","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669104701?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:42","pubTimestamp":1790156528,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，该公司于2026年9月23日斥资1137.23万元人民币回购25万股A股，每股回购价格为45.42-45.54元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03188","159982","LU1064131003.USD","LU1997244956.HKD","LU1820825898.SGD","LU0359202008.SGD","BK0060","82846","BK1147","LU0359201885.HKD","LU2097828631.EUR","LU2097828474.EUR","01276","BK0012","LU2495084118.USD","07233","LU2097828714.EUR","02827","LU2580892789.USD","LU0405327148.USD","LU1997245094.SGD","BK1191","LU0405327494.USD","BK0196","LU2580892862.HKD","83188","600276","LU1064130708.USD","LU1146622755.USD","BK0239","LU1255011170.USD","LU1781817850.SGD","LU1997245177.USD","LU1023057109.AUD","LU1580142542.USD","BK0188","02846","LU1328615791.USD","LU1969619763.USD","LU0359201612.USD","LU2097828557.USD","LU2289578879.USD","BK0028","399300","LU2097828805.USD","03130","LU2543165471.USD","BK0183","83130","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669392101","title":"恒瑞医药：HRS-7172片等多款药物临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2669392101","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669392101?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:54","pubTimestamp":1790153674,"startTime":"0","endTime":"0","summary":"恒瑞医药(600276)9月23日公告，近日，公司及子公司收到国家药监局核准签发关于HRS-7172片、阿得贝利单抗注射液、SHR-4610注射液、SHR-8068注射液、注射用SHR-9839（sc）、注射用SHR-1826、贝伐珠单抗注射液、HRS-4642注射液、HRS-6093片、HRS-7058胶囊的《药物临床试验批准通知书》，将于近期开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609233882480044.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609233882480044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201885.HKD","BK0012","PSYK","BK0028","BK0183","LU2328871848.SGD","MDTX","LU1997245094.SGD","LU2097828805.USD","LU1997244956.HKD","LU1064130708.USD","LU1146622755.USD","LU2488822045.USD","01276","LU2097828557.USD","LU2543165471.USD","BK0060","LU1969619763.USD","LU2495084118.USD","LU2580892862.HKD","LU1997245177.USD","LU0359201612.USD","LU2097828474.EUR","IBBQ","IBBJ","LU0405327494.USD","BK0196","BMED","LU1580142542.USD","LU2289578879.USD","LU1655091616.SGD","600276","LU2148510915.USD","LU2097828714.EUR","LU1328615791.USD","BK0188","LU0359202008.SGD","LU0405327148.USD","LU1820825898.SGD","BK1191","LU1023057109.AUD","LU1781817850.SGD","LU2097828631.EUR","LU2580892789.USD","BK0239","LU1255011170.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669017165","title":"先声药业周云曙：对外授权是阶段性选择，未来不再简单追求数量","url":"https://stock-news.laohu8.com/highlight/detail?id=2669017165","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669017165?lang=zh_cn&edition=full","pubTime":"2026-09-23 10:23","pubTimestamp":1790130233,"startTime":"0","endTime":"0","summary":"国产创新药出海BD（对外授权）交易火热，“卖青苗”争议随之而来，部分本土企业将早期管线海外权益提前授权给跨国药企，这种模式可以分担研发风险、验证中国创新价值，却也存在优质资产价值被低估的隐忧。如何兼顾短期生存与长期产业收益，成为中国创新药企出海需要权衡的命题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609233882254548.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609233882254548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","BK0028","LU2495084118.USD","LU2097828714.EUR","LU1997245177.USD","LU1781817850.SGD","LU1997244956.HKD","LU2097828474.EUR","02096","LU2289578879.USD","BK0239","BK0012","LU0405327148.USD","600276","LU1064131003.USD","LU2148510915.USD","LU1969619763.USD","BK0196","LU1655091616.SGD","LU1820825898.SGD","BK0188","LU2097828631.EUR","LU1255011170.USD","LU2328871848.SGD","LU1146622755.USD","LU1064130708.USD","BK0183","LU2097828805.USD","LU2097828557.USD","BK1191","LU2580892862.HKD","LU1997245094.SGD","LU2580892789.USD","BK0060","LU1328615791.USD","LU1580142542.USD","BK1583","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669199931","title":"“最大教训是创新转型不够快” 先声药业总裁周云曙：希望BD成为公司第二增长曲线","url":"https://stock-news.laohu8.com/highlight/detail?id=2669199931","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669199931?lang=zh_cn&edition=full","pubTime":"2026-09-22 14:34","pubTimestamp":1790058840,"startTime":"0","endTime":"0","summary":"作为国内头部传统药企，近年来，先声药业(HK02096)的创新转型步伐明显加快。2026年上半年，公司的创新药收入为38.9亿元，同比增长34.1%，在集团收入中占比84.9%，较2020年全年的45.1%提升显 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260922/c680164515.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260922/c680164515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU1997245177.USD","600276","LU2328871848.SGD","LU2097828474.EUR","BK0028","LU2148510915.USD","LU1969619763.USD","LU2097828805.USD","LU1820825898.SGD","BK0188","BK0060","BK0183","LU1655091616.SGD","LU2580892789.USD","LU2097828714.EUR","LU2097828631.EUR","LU2289578879.USD","BK0012","LU2580892862.HKD","LU1255011170.USD","LU1328615791.USD","LU0405327494.USD","LU1997245094.SGD","LU2488822045.USD","BK0196","LU1781817850.SGD","LU1997244956.HKD","LU0405327148.USD","LU1146622755.USD","LU2495084118.USD","LU1064130708.USD","LU1064131003.USD","BK0239","LU2097828557.USD","LU1580142542.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669115104","title":"贝莱德在恒瑞医药的H股好仓比例上升0.06%至7.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669115104","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669115104?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:21","pubTimestamp":1789982481,"startTime":"0","endTime":"0","summary":"南财智讯9月21日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在恒瑞医药的H股好仓（L）比例于9月16日从6.99%上升至7.05%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609213880077688.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609213880077688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","LU2097828474.EUR","600276","LU1655091616.SGD","BK0183","LU1997245177.USD","BK0012","LU2495084118.USD","LU2097828631.EUR","LU1328615791.USD","LU2580892862.HKD","LU1064131003.USD","BK0060","LU1820825898.SGD","LU2543165471.USD","LU1064130708.USD","LU1580142542.USD","LU2148510915.USD","LU1997245094.SGD","BK1191","LU2097828557.USD","LU0405327494.USD","LU2289578879.USD","BK0028","LU2097828714.EUR","LU1023057109.AUD","BK0239","LU2097828805.USD","BK0188","LU2580892789.USD","LU1146622755.USD","01276","LU1997244956.HKD","BK0196","LU1781817850.SGD","LU2328871848.SGD","LU1255011170.USD","LU0359201885.HKD","LU0359202008.SGD","LU0405327148.USD","LU2488822045.USD","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669590641","title":"恒瑞医药：HRS-1596片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2669590641","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669590641?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:57","pubTimestamp":1789981039,"startTime":"0","endTime":"0","summary":"南财智讯9月21日电，恒瑞医药公告，HRS-1596片收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展体重管理适应症和2型糖尿病适应症的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609213880059672.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609213880059672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828805.USD","LU2580892862.HKD","LU1146622755.USD","LU2097828474.EUR","LU2289578879.USD","01276","LU0359201612.USD","LU1781817850.SGD","LU0405327494.USD","BMED","LU2097828631.EUR","LU2097828557.USD","BK0239","LU1255011170.USD","IBBJ","600276","LU1328615791.USD","LU1997245094.SGD","LU1969619763.USD","LU1064130708.USD","LU0359201885.HKD","LU1023057109.AUD","LU0405327148.USD","BK1191","LU1997244956.HKD","LU2328871848.SGD","LU2543165471.USD","LU1655091616.SGD","BK0188","LU2148510915.USD","BK0196","BK0060","LU1820825898.SGD","LU0359202008.SGD","BK0012","LU1997245177.USD","MDTX","BK0028","LU2580892789.USD","PSYK","LU1064131003.USD","LU1580142542.USD","LU2097828714.EUR","BK0183","LU2488822045.USD","LU2495084118.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669597551","title":"恒瑞医药(600276.SH)：注射用SHR-4595获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2669597551","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669597551?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:54","pubTimestamp":1789980872,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局核准签发关于注射用SHR-4595的《药物临床试验批准通知书》，将于近期开展临床试验。注射用SHR-4595是公司自主研发的一款治疗用生物制品，可特异性结合肿瘤细胞表面抗原，杀伤肿瘤细胞，拟用于治疗晚期恶性实体瘤。经查询，国内外有一款与本品采用相同靶点的药物已获批上市。截至目前，注射用SHR-4595相关项目累计研发投入约为1,640万元(未经审计)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327148.USD","LU2495084118.USD","BK0060","LU1820825898.SGD","BK1191","LU2097828714.EUR","IBBQ","LU2097828557.USD","LU2328871848.SGD","LU1997245094.SGD","LU2097828474.EUR","01276","LU0359201885.HKD","LU2543165471.USD","LU1328615791.USD","LU1580142542.USD","LU2580892862.HKD","MDTX","BK0196","600276","BK0183","LU1064131003.USD","LU1781817850.SGD","LU1997245177.USD","LU2148510915.USD","LU0359201612.USD","LU1655091616.SGD","LU1997244956.HKD","LU0359202008.SGD","BK0028","LU1146622755.USD","LU2097828805.USD","IBBJ","LU1023057109.AUD","LU2097828631.EUR","PSYK","BK0012","BK0239","LU2289578879.USD","BK0188","LU1969619763.USD","BMED","LU1255011170.USD","LU2488822045.USD","LU0405327494.USD","LU2580892789.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669715850","title":"花旗：医药工业发展“十五五”规划利好创新药及医疗器械，首选恒瑞医药及信达生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2669715850","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669715850?lang=zh_cn&edition=full","pubTime":"2026-09-21 14:24","pubTimestamp":1789971840,"startTime":"0","endTime":"0","summary":"9月21日消息，花旗发表研报指，工信部等部门联合发布《医药工业发展“十五五”规划》，核心是推动中国医药工业由规模驱动增长转向创新驱动、质量导向发展，并明确提出到2030年跻身世界领先 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260921/c680119417.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260921/c680119417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU1064130708.USD","LU0405327148.USD","LU2580892789.USD","BK0012","BK0196","LU2289578879.USD","159883","LU1997245094.SGD","LU2328871848.SGD","BK0183","LU2097828714.EUR","LU1064131003.USD","LU1820825898.SGD","LU2580892862.HKD","LU2148510915.USD","LU1580142542.USD","LU1655091616.SGD","LU2488822045.USD","LU2097828557.USD","159992","LU2097828805.USD","LU1781817850.SGD","BK0060","BK0028","LU2097828631.EUR","LU1146622755.USD","LU1255011170.USD","LU0405327494.USD","LU1997245177.USD","LU2097828474.EUR","BK0239","600276","LU1969619763.USD","BK0188","LU1997244956.HKD","LU2495084118.USD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669130987","title":"大行评级丨美银：中国医疗保健行业加快创新及全球化，维持对信达生物、恒瑞医药“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669130987","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669130987?lang=zh_cn&edition=full","pubTime":"2026-09-21 14:09","pubTimestamp":1789970950,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","LU1580142542.USD","LU1969619763.USD","LU2097828474.EUR","LU1781817850.SGD","BK1589","LU0359201885.HKD","LU0405327148.USD","LU0359202008.SGD","BK1191","LU2097828805.USD","LU0244354667.USD","01276","BK1161","LU2097828714.EUR","LU1064130708.USD","LU0326950275.SGD","LU2543165471.USD","LU1997245177.USD","LU1820825898.SGD","LU2289578879.USD","KURE","01801","LU1146622755.USD","LU1255011170.USD","BK0183","LU2097828557.USD","LU2580892789.USD","LU1328615791.USD","LU1023057109.AUD","LU2097828631.EUR","600276","LU1655091616.SGD","LU2488822045.USD","BK0060","LU1064131003.USD","BK0196","BK0188","LU0405327494.USD","BK0012","LU0359201612.USD","LU1188198961.HKD","LU2148510915.USD","LU2328871848.SGD","LU1997244956.HKD","LU0455707207.USD","LU0502904849.HKD","LU1997245094.SGD","LU2495084118.USD","LU1831875114.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668945848","title":"研报掘金丨浙商证券：维持恒瑞医药“买入”评级，非肿瘤新药放量显著，BMS合作再创佳绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2668945848","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668945848?lang=zh_cn&edition=full","pubTime":"2026-09-18 15:30","pubTimestamp":1789716627,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0012","601878","BK0239","LU1969619763.USD","600276","LU1820825898.SGD","LU2488822045.USD","LU1328615791.USD","LU1255011170.USD","LU1064131003.USD","BK0276","LU1064130708.USD","BK0060","BK0183","LU2097828631.EUR","BK0196","BK0028","LU2097828474.EUR","LU2097828714.EUR","LU2097828557.USD","LU1997244956.HKD","LU2148510915.USD","LU2580892862.HKD","LU1655091616.SGD","LU2097828805.USD","LU0405327494.USD","LU1580142542.USD","LU1781817850.SGD","LU2289578879.USD","LU1146622755.USD","LU2495084118.USD","LU0405327148.USD","LU1997245177.USD","LU2580892789.USD","LU2328871848.SGD","LU1997245094.SGD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668933919","title":"港股异动 | 恒瑞医药(01276)涨近4% 公司首次回购A股 机构看好非肿瘤领域继续贡献产品端增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2668933919","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668933919?lang=zh_cn&edition=full","pubTime":"2026-09-18 10:12","pubTimestamp":1789697542,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药(01276)涨近4%，截至发稿，涨3.2%，报45.8港元，成交额5953.73万港元。消息面上，恒瑞医药发布公告，于2026年9月17日斥资1450.36万元回购33.5万股A股。浙商证券研报指出，2026H1公司创新药销售收入88.09亿元，同比增长16.38%，占药品销售收入的63.16%。其中，非肿瘤创新产品收入25.45亿元，同比增长73.97%，贡献约87%的创新药收入增量，增长主要来自恒格列净以及新纳入医保的艾玛昔替尼、夫那奇珠单抗和瑞卡西单抗。该行认为，随着新纳入医保产品逐步放量，看好非肿瘤领域继续贡献产品端增量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327148.USD","LU1655091616.SGD","LU2580892862.HKD","LU1064130708.USD","LU1997245177.USD","83188","LU0405327494.USD","83130","03130","159982","BK0188","LU2097828631.EUR","82846","LU1997245094.SGD","LU0359201612.USD","LU1064131003.USD","LU1023057109.AUD","03188","BK4585","BK0060","LU2328871848.SGD","BK0196","LU2097828805.USD","BK0012","LU1328615791.USD","600276","LU2097828714.EUR","LU2543165471.USD","LU2148510915.USD","BK1147","399300","VXUS","LU1146622755.USD","LU2488822045.USD","BK1191","LU1580142542.USD","LU1781817850.SGD","LU0359202008.SGD","02827","LU1255011170.USD","LU2580892789.USD","KCAI","01276","BK0239","07233","02846","BK4588","BK0028","LU2097828474.EUR","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668096820","title":"恒瑞医药(600276.SH)首次回购33.5万股 耗资1450.36万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668096820","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668096820?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:18","pubTimestamp":1789636700,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，2026年9月17日，公司通过集中竞价交易方式首次回购A股股份33.5万股，已回购股份占公司总股本的比例为0.005%，成交的最高价为43.58元/股，最低价为43.10元/股，已支付的总金额为1450.36万元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01276","LU0359201885.HKD","BK0196","LU1820825898.SGD","LU1064130708.USD","BK0183","LU0359201612.USD","600276","LU2097828631.EUR","BK0028","LU2097828474.EUR","LU2580892862.HKD","LU2097828805.USD","LU0359202008.SGD","LU0405327148.USD","LU1146622755.USD","BK1191","LU1655091616.SGD","LU2097828557.USD","LU2328871848.SGD","LU1064131003.USD","BK0188","LU1781817850.SGD","LU1997244956.HKD","LU2097828714.EUR","LU2543165471.USD","LU1580142542.USD","LU2488822045.USD","BK0060","LU2495084118.USD","LU2148510915.USD","LU1255011170.USD","LU1997245177.USD","LU2289578879.USD","LU0405327494.USD","LU1969619763.USD","LU1328615791.USD","BK0012","LU1023057109.AUD","LU2580892789.USD","LU1997245094.SGD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667605559","title":"港股异动 | 恒瑞医药(01276)尾盘涨近4% 同日获两份临床试验批准 覆盖银屑病和卒中预防","url":"https://stock-news.laohu8.com/highlight/detail?id=2667605559","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667605559?lang=zh_cn&edition=full","pubTime":"2026-09-16 15:49","pubTimestamp":1789544947,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药尾盘涨近4%。截至发稿，涨3.88%，报45.5港元，成交额1.53亿港元。消息面上，9月15日，恒瑞医药公告称，子公司福建盛迪医药的HRS-4139片获国家药监局临床试验批准，同意开展中重度斑块状银屑病的临床试验。同日，子公司广东恒瑞医药的注射用瑞卡西单抗获临床试验批准，同意开展Ⅲ期临床试验，适应证为用于颅内动脉粥样硬化性狭窄的成人患者以降低卒中复发风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2580892789.USD","BK1191","LU1580142542.USD","LU2495084118.USD","KCAI","LU2097828631.EUR","LU2543165471.USD","VXUS","BK0239","LU1655091616.SGD","IBBJ","BMED","LU1781817850.SGD","LU1064131003.USD","LU2097828805.USD","BK0183","01276","LU2328871848.SGD","LU1997245094.SGD","LU2289578879.USD","LU1969619763.USD","BK0012","IBBQ","600276","BK4588","LU0359201885.HKD","LU1146622755.USD","LU0359201612.USD","LU2580892862.HKD","LU1997245177.USD","BK0188","LU2148510915.USD","PSYK","LU1255011170.USD","LU1023057109.AUD","MDTX","BK0196","LU2097828474.EUR","LU1997244956.HKD","LU2097828714.EUR","BK4585","BK0028","LU2488822045.USD","LU0405327494.USD","LU1820825898.SGD","LU2097828557.USD","BK0060","LU0405327148.USD","LU1328615791.USD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617679","title":"创新药概念局部走强 恒瑞医药（01276）涨2.74% 机构料企业扭亏节点到来","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617679","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667617679?lang=zh_cn&edition=full","pubTime":"2026-09-16 10:20","pubTimestamp":1789525259,"startTime":"0","endTime":"0","summary":"消息面上，国金证券表示，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。诚通证券表示，2025年为创新药海外授权BD大年，2026H1我国创新药海外授权BD交易继续大幅增长，总交易金额已接近1000亿美元，国产创新药已从偶发性出海转变为系统性趋势。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991724","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327148.USD","LU0348827113.USD","LU2488822045.USD","LU2097828805.USD","BK0183","LU0561508036.HKD","LU2580892789.USD","LU0128526141.USD","BK0060","IE00BZ08YS42.EUR","LU0140636845.USD","LU0516422952.EUR","LU0516423174.USD","KURE","LNGR","LU1255011170.USD","600276","BK0239","LU0417516902.SGD","IE00B0JY6N72.USD","LU0348825331.USD","LU1023057109.AUD","LU1997244956.HKD","BK1574","LU2039709279.SGD","LU2148510915.USD","LU1328615791.USD","IBBQ","09688","02637","BK1515","01177","LU2097828557.USD","02269","LU0327786744.USD","LU0359201612.USD","LU0588546209.SGD","LU0307460666.USD","159992","LU0456846285.SGD","01276","MEDX","LU1580142542.USD","LU1820825898.SGD","BK0188","06978","LU1655091616.SGD","01477","LU0043850808.USD","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193798657","title":"港交所披露：贝莱德增持恒瑞医药H股，持股比例升至7.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193798657","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193798657?lang=zh_cn&edition=full","pubTime":"2026-09-15 17:30","pubTimestamp":1789464623,"startTime":"0","endTime":"0","summary":"据香港交易所最新权益披露数据，贝莱德对江苏恒瑞医药股份有限公司H股的长期持仓比例已悄然攀升。具体来看，截至9月10日，这家全球资产管理巨头的持股比例由先前的6.56%提升至7.17%。此次增持动作引发市场关注。在短短的时间内，贝莱德便将持仓水平推高了逾0.6个百分点，反映出其对恒瑞医药未来发展的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","LU1023057109.AUD","LU0359201612.USD","LU1997244956.HKD","LU1781817850.SGD","LU1146622755.USD","LU2580892862.HKD","BK0060","BK0183","BK0028","LU2543165471.USD","LU1969619763.USD","LU1997245094.SGD","LU0405327148.USD","01276","LU2580892789.USD","BK0239","LU1580142542.USD","LU2495084118.USD","LU1064130708.USD","LU0359201885.HKD","BK1191","LU1997245177.USD","LU1328615791.USD","LU2097828714.EUR","LU2488822045.USD","BK0196","LU0359202008.SGD","600276","LU1064131003.USD","LU2097828474.EUR","LU2097828805.USD","BK0188","LU2289578879.USD","LU1820825898.SGD","BK0012","LU1655091616.SGD","LU2148510915.USD","LU2097828631.EUR","LU0405327494.USD","LU2097828557.USD","LU1255011170.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667648964","title":"恒瑞医药：子公司“注射用瑞卡西单抗”获批开展III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2667648964","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667648964?lang=zh_cn&edition=full","pubTime":"2026-09-15 16:55","pubTimestamp":1789462500,"startTime":"0","endTime":"0","summary":"9月15日，恒瑞医药（600276/01276）发布公告，公司子公司广东恒瑞药有限公司近日收到国家药品监督管理局核准签发的关于注射用瑞卡西单抗的《药物临床试验批准通知书》，将于近期开展III期临床试验。该药物的适应症为颅内动脉粥样硬化性狭窄的成人患者，以降低卒中复发风险。2026年中期，恒瑞医药实现收入154.56亿元，归母净利润44.65亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153874740380.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153874740380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","PSYK","LU2580892862.HKD","LU2580892789.USD","01276","BMED","LU1655091616.SGD","LU1781817850.SGD","LU2097828714.EUR","LU0405327494.USD","LU0359201885.HKD","LU2097828805.USD","LU1580142542.USD","LU1023057109.AUD","MDTX","BK0012","LU1820825898.SGD","LU1969619763.USD","BK0188","LU1997244956.HKD","BK0060","LU1146622755.USD","LU0405327148.USD","BK0196","LU0359201612.USD","LU1997245177.USD","LU2543165471.USD","LU1255011170.USD","LU2495084118.USD","BK0183","LU1328615791.USD","LU2488822045.USD","IBBJ","IBBQ","LU1064131003.USD","600276","LU0359202008.SGD","LU2148510915.USD","LU2289578879.USD","LU2097828557.USD","BK1191","LU2097828631.EUR","LU2097828474.EUR","LU2328871848.SGD","LU1064130708.USD","BK0239","LU1997245094.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667610471","title":"恒瑞医药(600276.SH)：HRS-4139片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2667610471","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667610471?lang=zh_cn&edition=full","pubTime":"2026-09-15 16:39","pubTimestamp":1789461583,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-4139片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-4139片是公司自主研发的1类新药，在动物模型中，可有效改善银屑病症状，抑制炎症反应。经查询，国内外暂无相同靶点药物获批上市。截至目前，HRS-4139片相关项目累计研发投入约2,040万元(未经审计)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","LU0359201612.USD","LU1580142542.USD","LU2097828557.USD","BK0012","LU2328871848.SGD","LU2488822045.USD","BK0183","LU1146622755.USD","LU2097828805.USD","BK1191","LU1820825898.SGD","LU1997245177.USD","LU2097828474.EUR","LU2097828714.EUR","IBBQ","600276","LU1064131003.USD","LU1064130708.USD","BMED","MDTX","BK0060","BK0028","LU2289578879.USD","LU2097828631.EUR","LU0359202008.SGD","LU1997245094.SGD","LU2148510915.USD","LU2495084118.USD","LU2543165471.USD","LU1255011170.USD","LU0359201885.HKD","LU1023057109.AUD","LU1997244956.HKD","IBBJ","LU1328615791.USD","LU0405327148.USD","BK0196","LU1781817850.SGD","BK0239","01276","LU2580892789.USD","BK0188","LU2580892862.HKD","LU1655091616.SGD","LU0405327494.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667265224","title":"恒瑞医药：SHR-2004注射液上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2667265224","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667265224?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:49","pubTimestamp":1789379352,"startTime":"0","endTime":"0","summary":"9月14日，恒瑞医药公告称，公司子公司北京盛迪医药收到国家药监局下发的《受理通知书》，公司1类创新药、凝血因子XI单克隆抗体SHR-2004注射液的药品上市许可申请获受理。该药品拟定适应症为用于择期膝关节置换手术的成年患者，以预防静脉血栓形成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873526173.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873526173.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892789.USD","BK1191","LU1580142542.USD","LU2495084118.USD","LU2097828631.EUR","LU2543165471.USD","BK0239","LU1655091616.SGD","IPOS","LU1781817850.SGD","LU1064131003.USD","LU2097828805.USD","BK0183","01276","LU2328871848.SGD","LU1997245094.SGD","LU2289578879.USD","LU1969619763.USD","BK0012","600276","LU0359201885.HKD","LU1146622755.USD","LU0359201612.USD","LU2580892862.HKD","LU1997245177.USD","BK0188","LU2148510915.USD","LU1064130708.USD","LU1255011170.USD","LU1023057109.AUD","BK0196","LU2097828474.EUR","LU1997244956.HKD","LU2097828714.EUR","BK0028","LU2488822045.USD","LU0405327494.USD","LU1820825898.SGD","LU2097828557.USD","BK0060","LU0405327148.USD","LU1328615791.USD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790245733402,"stockEarnings":[{"period":"1week","weight":0.0473},{"period":"1month","weight":-0.0252},{"period":"3month","weight":-0.0891},{"period":"6month","weight":-0.1706},{"period":"1year","weight":-0.3434},{"period":"ytd","weight":-0.2317}],"compareEarnings":[{"period":"1week","weight":0.0115},{"period":"1month","weight":0.014},{"period":"3month","weight":-0.0446},{"period":"6month","weight":0.0058},{"period":"1year","weight":0.03},{"period":"ytd","weight":-0.0081}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"539148人(较上一季度增加17.64%)","perCapita":"11831股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是注射用卡瑞利珠单抗、羟乙磺酸达尔西利片、瑞维鲁胺片、海曲泊帕乙醇胺片、脯氨酸恒格列净片、碘佛醇注射液。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}